---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-21-001387"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T10:02:42.930909+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Edgewise reports Q3 net loss $12.9M; positive Phase 1 MAD data for EDG-5506

## Summary
- Cash, cash equivalents and marketable securities of $290M as of Sept 30, 2021.
- R&D expenses $9.9M (Q3 2021) vs $3.2M (Q3 2020), increase due to Phase 1 trial and headcount.
- Net loss $12.9M ($0.26/share) compared to $3.6M in Q3 2020.
- Positive EDG-5506 Phase 1 MAD topline: well tolerated, target engagement, no effect on voluntary strength or cardiac myosin.
- First BMD patients dosed in Phase 1b; Phase 2 trials in BMD and DMD expected to start in 2022.

## SEC filing metadata
- accession: 0001157523-21-001387
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000115752321001387/0001157523-21-001387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000115752321001387/a52527144.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-21-001387
- JSON: https://secwatch.observer/filing/0001157523-21-001387.json
- Plain text: https://secwatch.observer/filing/0001157523-21-001387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.